[The benefits of carvedilol therapy in the treatment of patients with high cardiovascular risk]. / A carvedilolterápia elonyei magas cardiovascularis kockázatú betegek kezelése során.

Among the variety of cardiologic pharmacological therapy options, beta-blockers stand on a prominent position. There are several reasons for this. On one hand they have numerous indication rounds, even though professional guidelines have recently tended to de-emphasize them for treatments of hypertension without complication or comorbidity. However, in addition to hypertonic cases associated with cardiac complication, they play a fundamental role in treating heart failure and arrhythmia and the different clinical manifestations (stable angina pectoris, myocardial state) of ischemic heart disease. The decade long development of the pharmacological group made its hemodynamic effects ever more refined. On the other hand we must not neglect the fact that more and more features came to light that positively influence the outcome of cardiovascular diseases. Verification of these latter features in numerous multicentric studies showed how to achieve a beneficial effect on survivability, independent on even hemodynamic effects during beta-blocker therapy.

[Role of trimetazidine in the treatment of diabetic microangiopathy in ischaemic heart disease]. / A trimetazidin szerepe a diabeteses microangiopathia kezelésében ischaemiás szívbetegség esetén.

Diabetes is one of the largest public health problems nowadays. We have to consider appearance of micro- and macroangiopathic complications as early as the time of diagnosis. In diabetes mellitus type 2, one of the main complications is ischemic heart disease caused by atherosclerosis of the coronary arteries manifested clinically as angina pectoris and myocardial infarction. However, microangiopathy and secondary injury of myocardial tissue are also not uncommon complications. In the treatment of ischemic heart disease coronary interventions, medications dilating coronaries and decreasing blood pressure and heart rate are frequently applied. The authors draw attention to a drug having no hemodynamic effects, which improves the quality of life of patients via its effect on the metabolism of the myocardium.

[Empyema thoracis, hemorrhagic pericarditis and acalculous cholecystitis caused by Eikenella corrodens sepsis]. / Empyemát, haemorrhagiás pericarditist és acalculosus cholecystitist okozó Eikenella corrodens szepszis.

The authors present a case of a 29-year-old woman who was diagnosed with pneumonia in the left side complicated with pleural effusion and hemorrhagic pericarditis one month after she had undergone tonsillectomy. Eikenella corrodens was identified as pathogenic agent when the empyema was removed during thoracotomy. After the patient was given antibiotic treatment she was discharged from the hospital without any symptoms or complaints. However, one month after she had left the hospital she was readmitted to the surgical unit as an emergency because of acute abdominal complaints. On admission acalculous cholecystitis as well as hemorrhagic pericarditis requiring pericardiocentesis were also observed. A rare cause of sepsis, Eikenella corrodens was identified which resulted in a severe disorder including polyserositis. Pericardiocentesis was performed two times and the patient was given targeted antibiotics and non-steroidal anti-inflammatory drugs. She was also treated with antimycotics as she had developed mycosis. After one month the patient recovered and was discharged from the hospital. No further recurrence of symptoms or complaints was observed during follow up.